Review
Copyright ©The Author(s) 2021.
World J Gastrointest Surg. Sep 27, 2021; 13(9): 885-903
Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.885
Table 1 Prognostic role of nutritional status changes during neoadjuvant therapy in patients with pancreatic cancer
Ref.
Number of patients enrolled
Neoadjuvant treatment
Body composition changes (P value)
Body parameters and clinical outcomes (HR; P value)
Naumann et al[35], 2013, Retrospective100Gemcitabine-based chemoradiationWeight decrease (P < 0.0001), BMI decrease (P < 0.0001), SAT decrease (P < 0.0001)WL tended to negatively impact on OS (P > 0.05)
Cooper et al[36], 2015, Retrospective89Gemcitabine and Cisplatin followed by Gemcitabine-based chemoradiationSKM area/height2 decrease (P = 0.01), VAT area/height2 decrease (P = 0.01), SAT/height2 decrease (P = 0.02)Loss of SKM was related to a shorter DFS (HR 0.89, P = 0.04), loss of VAT was related to shorter PFS (HR 0.97, P = 0.01) and OS (HR 0.97, P = 0.001)
Cloyd et al[37], 2018, Retrospective127Gemcitabine, Capecitabine or 5-FU based chemoradiationSKM stability (P > 0.05), VAT decrease (P < 0.001), SAT decrease (P = 0.02)Body composition changes during were not associated with OS (P > 0.05)
Sandini et al[40], 2018, Retrospective193FOLFIRINOX-based chemoradiotherapyTAT area decrease (P < 0.001), VAT area decrease (P < 0.0001), SKM area increase (P < 0.0001)SKM area/height2 was higher in patients who underwent resection (P = 0.004)
Naumann et al[38], 2019, Retrospective147Gemcitabine-based chemoradiationWeight decrease (P < 0.0001), SKM area decrease (P < 0.0001)WL > 5% was associated with poor OS (HR 1.56, P = 0.028), SKM area loss > 5% was associated with poor OS (HR 1.50, P = 0.036)
Griffin et al[41], 2019, Retrospective78FOLFIRINOX and gemcitabine-based treatmentsSKM area decrease (P < 0.0001), VAT decrease (P < 0.0001), SAT decrease (P < 0.0001)Loss of lean mass was related to poor OS (HR 1.1, P = 0.003), loss of SKM was related to poor OS (HR 1.21, P = 0.001)
Naumann et al[39], 2019, Retrospective141Gemcitabine-based chemoradiationWeight decrease (P < 0.001), BMI decrease (P < 0.0001), SAT, VAT and SKM areas decrease (P < 0.0001)WL > 5% was associated with worse OS (HR 2.8, P = 0.009), SKM area loss > 5% was associated with poor OS (HR 5.54, P < 0.001)